Commissioner and Commission Staff Public Statements and Letters

Displaying 101 - 120 of 311

Joint FDA/FTC Warning Letter Concerning Product Labeling of Human Chrorionic Gonadotropin (HCG) Drugs

LaTonya Mitchell, Director, Food and Drug Administration (FDA) Denver District Office; and Dr. Ilisa Bernstein, Acting Director, FDA Office of Compliance to Dr. Gary Arbuckle and Ms. Amy Freeze, theoriginalncgdrops.com and resetthebody.com

Date:
By: 
Mary K. Engle, Associate Director

Mary K. Engle

Pages